At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 236 enrolled
Drug / intervention
RO7234292 (RG6042)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Intrathecally Administered RO7234292 (RG6042) in Patients With Huntington's Disease
In Brief
A Phase 3 clinical trial evaluating RO7234292 (RG6042) for Huntington Disease. Completed, enrolled 236 participants across 38 sites in 8 countries.
Detailed Summary
This study will evaluate the long-term safety and tolerability of RO7234292 (RG6042) in participants who have completed other F. Hoffmann-La Roche, Ltd.-sponsored and/or Genentech-sponsored studies in the Huntington's disease (HD) in the development program for RG6042.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesAustria, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartApr 2019
Primary CompletionMar 2022
Study CompletionMar 2022
TodayJul 2026
First PostedFeb 15, 2019
Enrollment StartApr 23, 2019
Primary CompletionMar 25, 2022
Study CompletionMar 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.4 years ago
Interventions
RO7234292 (RG6042)drug
Intrathecal injection